The Latest Cardiac and Vascular News
OAKLAND, Calif., Nov. 25, 2024 /PRNewswire/ — Koya Medical, a leading medical device company pioneering solutions in vascular care, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:50 pm ET. Koya CEO, Andy…
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte’s acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in patients with end stage renal disease at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) in New York, NY on November 23, 2024.
Niagara Falls, NY, Nov. 21, 2024 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce its agreement with Upbeat Cardiology Solutions to supply its PET-CT Systems and Services. This cooperation aims to empower cardiology practices with advanced imaging technology and turnkey solutions which streamline the adoption of cardiac PET-CT imaging to deliver unparalleled healthcare to patients.
Trial completion marks an important milestone in the development of the next generation, embolic protection platform MINNEAPOLIS, Nov. 21, 2024 /PRNewswire/ — Cardiovascular medical device company, EmStop, Inc., today announced the completion of the CAPTURE-1 early feasibility clinical…
BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma in the New England Journal of Medicine. The study shows that among patients with symptomatic chronic subdural hematoma (cSDH), adjunctive middle meningeal artery (MMA) embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. STEM is the first randomized prospective IDE trial investigating embolization of the MMA for the treatment of cSDH.
SEISMIC-HF I enrolled a large, demographically diverse population across 15 sites Results are an important step toward enabling widespread, non-invasive hemodynamic-guided heart failure management CHICAGO, Nov. 20, 2024 /PRNewswire/ — Cardiosense, a medical AI company transforming the…
Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies Medtronic plc, a global leader in healthcare technology, today announced it began a randomized study sponsored by Tempus, a technology company leading the adoption […]
Akumin Introduces AXIS – Reimagining How Radiology and Oncology Services Are Delivered PLANTATION, FL, Nov. 20, 2024 /PRNewswire/ – Akumin, a leader in managed radiology and oncology services, is proud to launch Akumin AXIS Expandable Patient Solutions™ at RSNA 2024. The Akumin AXIS unit…
EchoGo® Amyloidosis is an AI-based software-only medical device, which aims to improve early detection of Cardiac Amyloidosis, an underdiagnosed cause of heart failure. EchoGo® Amyloidosis sits on Ultromics’ EchoGo® platform complementing the existing commercialized EchoGo® Heart Failure…
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
